Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Rothermel, T. McKinsey, Rick Vega, R. Nicol, P. Mammen, John Yang, C. Antos, J. Shelton, R. Bassel-Duby, E. Olson, R. Williams (2001)
Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivoProceedings of the National Academy of Sciences of the United States of America, 98
Alexander Swirnoff, E. Apel, J. Svaren, Brad Sevetson, D. Zimonjic, N. Popescu, J. Milbrandt (1998)
Nab1, a Corepressor of NGFI-A (Egr-1), Contains an Active Transcriptional Repression DomainMolecular and Cellular Biology, 18
Stephen Lee, Y. Sadovsky, Alexander Swirnoff, J. Polish, Pam Goda, G. Gavrilina, J. Milbrandt (1996)
Luteinizing Hormone Deficiency and Female Infertility in Mice Lacking the Transcription Factor NGFI-A (Egr-1)Science, 273
M. Lohse, S. Engelhardt, T. Eschenhagen (2003)
What Is the Role of &bgr;-Adrenergic Signaling in Heart Failure?Circulation Research: Journal of the American Heart Association, 93
J. Towbin, N. Bowles (2002)
The failing heartNature, 415
S. Engelhardt, L. Hein, F. Wiesmann, M. Lohse (1999)
Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice.Proceedings of the National Academy of Sciences of the United States of America, 96 12
Mark Sussman, H. Lim, N. Gude, T. Taigen, E. Olson, J. Robbins, M. Colbert, A. Gualberto, D. Wieczorek, J. Molkentin (1998)
Prevention of cardiac hypertrophy in mice by calcineurin inhibition.Science, 281 5383
Antonio Rapacciuolo, Giovanni Esposito, K. Caron, Lan Mao, Steven Thomas, H. Rockman (2001)
Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy.Journal of the American College of Cardiology, 38 3
M Buvoli, LA Leinwand (2002)
Direct gene transfer into mouse heartMethods Enzymol., 346
K. Li, R. Welikson, K. Vikstrom, L. Leinwand (1997)
Direct gene transfer into the mouse heart.Journal of molecular and cellular cardiology, 29 5
Chun-li Zhang, T. McKinsey, Shurong Chang, C. Antos, Joseph Hill, E. Olson (2002)
Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac HypertrophyCell, 110
J. Milbrandt (1987)
A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor.Science, 238 4828
P. Topilko, S. Schneider-Maunoury, G. Levi, A. Evercooren, Amina Chennoufi, T. Seitanidou, C. Babinet, P. Charnay (1994)
Krox-20 controls myelination in the peripheral nervous systemNature, 371
G. Esposito, A. Rapacciuolo, S. Prasad, H. Takaoka, S. Thomas, W. Koch, H. Rockman (2002)
Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall StressCirculation: Journal of the American Heart Association, 105
M. Crackower, G. Oudit, I. Kozieradzki, R. Sarao, Hui Sun, Takehiko Sasaki, E. Hirsch, A. Suzuki, T. Shioi, J. Irie-Sasaki, R. Sah, H. Cheng, V. Rybin, G. Lembo, L. Fratta, A. Oliveira-dos-Santos, Jeffery Benovic, C. Kahn, S. Izumo, S. Steinberg, M. Wymann, P. Backx, J. Penninger (2002)
Regulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling PathwaysCell, 110
N. Frey, H. Katus, E. Olson, Joseph Hill (2004)
Hypertrophy of the heart: a new therapeutic target?Circulation, 109 13
A. Gashler, V. Sukhatme (1995)
Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors.Progress in nucleic acid research and molecular biology, 50
Mark Russo, Brad Sevetson, Jeffrey Milbrandt (1995)
Identification of NAB1, a repressor of NGFI-A- and Krox20-mediated transcription.Proceedings of the National Academy of Sciences of the United States of America, 92 15
J. Sadoshima, L. Jahn, Toshiyuki Takahashi, T. Kulik, S. Izumo (1992)
Molecular characterization of the stretch-induced adaptation of cultured cardiac cells. An in vitro model of load-induced cardiac hypertrophy.The Journal of biological chemistry, 267 15
D. Lévy, R. Garrison, D. Savage, W. Kannel, W. Castelli (1990)
Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.The New England journal of medicine, 322 22
D. Allen, B. Harrison, A. Maass, Matthew Bell, W. Byrnes, L. Leinwand (2001)
Cardiac and skeletal muscle adaptations to voluntary wheel running in the mouse.Journal of applied physiology, 90 5
Joseph Hill, B. Rothermel, K. Yoo, B. Cabuay, E. Demetroulis, Robert Weiss, W. Kutschke, R. Bassel-Duby, R. Williams (2002)
Targeted Inhibition of Calcineurin in Pressure-overload Cardiac HypertrophyThe Journal of Biological Chemistry, 277
H. Yasukawa, T. Yajima, H. Duplain, M. Iwatate, M. Kido, M. Hoshijima, M. Weitzman, Tomoyuki Nakamura, S. Woodard, Dingding Xiong, A. Yoshimura, K. Chien, K. Knowlton (2003)
The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury.The Journal of clinical investigation, 111 4
O. Bueno, L. Windt, Hae Lim, Kevin Tymitz, S. Witt, T. Kimball, J. Molkentin (2001)
The Dual-Specificity Phosphatase MKP-1 Limits the Cardiac Hypertrophic Response In Vitro and In VivoCirculation Research: Journal of the American Heart Association, 88
L. Warner, P. Mancias, I. Butler, Craig McDonald, L. Keppen, K. Koob, J. Lupski (1998)
Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathiesNature Genetics, 18
John Svaren, Brad Sevetson, Elizabeth Apel, D. Zimonjic, N. Popescu, Jeffrey Milbrandt (1996)
NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuliMolecular and Cellular Biology, 16
J. Molkentin, G. Dorn (2001)
Cytoplasmic signaling pathways that regulate cardiac hypertrophy.Annual review of physiology, 63
K. Chien, E. Olson (2002)
Converging Pathways and Principles in Heart Development and Disease CV@CSHCell, 110
G. Thiel, G. Cibelli (2002)
Regulation of life and death by the zinc finger transcription factor Egr‐1Journal of Cellular Physiology, 193
Ludwig Neyses, Janis Nouskas, Hans Vetter (1991)
Inhibition of endothelin-1 induced myocardial protein synthesis by an antisense oligonucleotide against the early growth response gene-1.Biochemical and biophysical research communications, 181 1
JA Hill (2002)
Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic functionJ. Biol. Chem., 277
K. Livak, Thomas Schmittgen (2001)
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.Methods, 25 4
G. Dorn, J. Robbins, P. Sugden (2003)
Phenotyping hypertrophy: eschew obfuscation.Circulation research, 92 11
J. Svaren, Brad Sevetson, T. Golda, J. Stanton, Alexander Swirnoff, J. Milbrandt (1998)
Novel mutants of NAB corepressors enhance activation by Egr transactivatorsThe EMBO Journal, 17
J. Molkentin, Jian-rong Lu, C. Antos, B. Markham, J. Richardson, J. Robbins, S. Grant, E. Olson (1998)
A Calcineurin-Dependent Transcriptional Pathway for Cardiac HypertrophyCell, 93
N. Saadane, L. Alpert, L. Chalifour (2000)
Altered molecular response to adrenoreceptor-induced cardiac hypertrophy in Egr-1-deficient mice.American journal of physiology. Heart and circulatory physiology, 278 3
L. Neyses, J. Nouskas, J. Luyken, S. Fronhoffs, Silke Oberdorf, Ulrich Pfeifer, R. Williams, V. Sukhatme, H. Vetter (1993)
Induction of immediate-early genes by angiotensin II and endothelin-1 in adult rat cardiomyocytesJournal of Hypertension, 11
Hypertrophy represents the major physiological response of the heart to adapt to chronically enhanced workload, but is also crucial in the development of heart failure. Although we know of numerous inducers of cardiac hypertrophy, little is known about mechanisms that limit cardiac hypertrophy. Here, we describe the transcriptional repressor NAB1 as an endogenous regulator of cardiac growth. We identified NAB1 as being upregulated in both mouse and human heart failure. Nab1 is highly expressed in mammalian cardiac myocytes and it inhibited cardiomyocyte hypertrophy through repression of its targets, transcription factor Egr. Transgenic mice with cardiac-specific overexpression of Nab1 showed that Nab1 is a potent inhibitor of cardiac growth in response to pathological stimuli in vivo. Nab1 overexpression suppressed adrenergically induced and pressure overload–induced hypertrophy, whereas physiological growth during development and in response to exercise was not affected. These findings implicate the Nab1-Egr1 axis as a crucial regulator of pathological cardiac growth.
Nature Medicine – Springer Journals
Published: Jul 17, 2005
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.